Celltrion’s potential COVID-19 therapy reduces virus by 100 times in animal tests
IndustryJun 1, 2020
Celltrion on Monday announced that its antiviral COVID-19 treatment candidate CT-P59 reduced the amount of SARS-CoV-2 virus in infected ferrets 100-fold in preclinical trial results, with significant improvements in lung lesions. The company said it will proceed with the first human clinical trials in July. If the results are replicated in human test subjects, CT-P59 will gain an edge in potentially becoming an acknowledged therapy for the ongoing global pandemic. “Celltrion is drawing